Antibody-drug conjugate development

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications

Volumn , Issue , 2013, Pages 23-38

  Khandelwal, Aakanksha ^a   Saber, Haleh ^a   Shapiro, Marjorie A ^a   Zhao, Hong ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896774630     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5456-4_2     Document Type: Chapter

References (46)

1. Ducry L, Stump B (2010) Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21(1):5-13
2. Barok M et al (2011) Trastuzumab-DM1 causes tumor growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 13(2):R46
3. Barok M et al (2007) Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6(7):2065-2072
4. Remillard S et al (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189(4207): 1002-1005
5. DiJoseph JF et al (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5):1807-1814
6. Advani A et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotu- zumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28(12):2085-2093
7. Younes A et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363(19):1812-1821
8. FDA (1997) Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use, CBER, Editor: Rockville, weblink last assessed January 3, 2012: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/OtherRecommendationsforManufacturers/UCM153182.pdf
9. FDA (2010) Guidance for Industry: ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals. Weblink last assessed January 3, 2012: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm085389.pdf
10. Alley SC, Okeley NM, Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14(4):529-537
11. FDA (1997) Guidance for Industry: ICH S6 Preclinical Safety Evaluation of Biotechnology- Derived Pharmaceuticals. Weblink last assessed January 3, 2012: http://www.fda.gov/down- loads/regulatoryinformation/guidances/ucm 129171 .pdf
12. FDA (1996) Guideline for Industry: ICH S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals. Weblink last assessed January 3, 2012: http://www.fda.gov/down- loads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074925.pdf
13. Bross PF et al (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490-1496
14. Law CL et al (2004) Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 10(23):7842-7851
15. Sutherland MS et al (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281 (15): 10540-10547
16. Alley SC et al (2008) Contribution of linker stability to the activities of anticancer immuno- conjugates. Bioconjug Chem 19(3):759-765
17. Lewis Phillips GD (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68(22):9280-9290
18. Sanderson RJ et al (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11(2 Pt 1):843-852
19. Kuang B, King L, Wang HF (2010) Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2(6):1125-1140
20. Krop IE et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28(16):2698-2704
21. DeSilva B et al (2003) Recommendations for the bioanalytical method validation of ligandbinding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 20(11):1885-1900
22. FDA (2001) Guidance for Industry: Bioanalytical Method Validation. Weblink last assessed January 3, 2012: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/ Guidances/ucm070107. pdf
23. Hamblett KJ et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063-7070
24. McDonagh CF et al (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19(7):299-307
25. Imanishi T, Makela O (1974) Inheritance of antibody specificity. I. Anti-(4-hydroxy-3- nitrophenyl)acetyl of the mouse primary response. J Exp Med 140(6):1498-1510
26. Imanishi T, Makela O (1974) Inheritance of fine-specificity in mouse anti-hapten antibodies. Ann Immunol (Paris) 125C(1-2):199-200
27. Bothwell AL et al (1981) Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region. Cell 24(3):625-637
28. Berek C, Griffiths GM, Milstein C (1985) Molecular events during maturation of the immune response to oxazolone. Nature 316(6027):412-418
29. Paul WE, Siskind GW (1970) Hapten specificity of cellular immune responses as compared with the specificity of serum anti-hapten antibody. Immunology 18(6):921-930
30. Yamashita U, Kitagawa M (1974) Induction of anti-hapten antibody response by hapten-isologous carrier conjugate. I. Development of hapten-reactive helper cells by hapten-isologous carrier. Cell Immunol 14(2):182-192
31. Harding FA et al (2010) The immunogenicity ofhumanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2(3):256-265
32. McKoy JM et al (2008) Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 48(8):1754-1762
33. Buttel IC et al (2011) Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39(2):100-109
34. Swann PG, Shapiro MA (2011) Regulatory considerations for development of bioanalytical assays for biotechnology products. Bioanalysis 3(6):597-603
35. Getts DR et al (2010) Have we overestimated the benefit of human(ized) antibodies? MAbs 2(6):682-694
36. FDA (2009) Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. Weblink last assessed January 3, 2012: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf
37. FDA (2005) Guidance for Industry: Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, CDER/CBER. Weblink last assessed January 3, 2012: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ ucm128076.pdf
38. FDA (2010) Draft Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and Impact on Dosing and Labeling. 2010; weblink last assessed January 3, 2012: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM204959.pdf
39. FDA (2003) Guidance for Industry: Exposure-Response Relationships-Study Design, Data Analysis, and Regulatory Applications. Weblink last assessed January 3, 2012: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072109.pdf
40. FDA (1999) Guidance for Industry: Population Pharmacokinetics. Weblink last assessed January 3, 2012: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealth Research/UCM133184.pdf
41. Rodriguez I et al (2010) Electrocardiographic assessment for therapeutic proteins-scientific discussion. Am Heart J 160(4):627-634
42. Curigliano G et al (2008) Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer 44(4):494-500
43. Rock EP et al (2009) Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J 157(5):827-836, 836.e1
44. Sarapa N, Britto MR (2008) Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opin Drug Saf 7(3):305-318
45. Lalonde RL, Honig P (2008) Clinical pharmacology in the era of biotherapeutics. Clin Pharmacol Ther 84(5):533-536
46. Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24(1):23-39